T-Mobile US, Inc. to Present at the Morgan Stanley Technology, Media & Telecom Conference
OS Therapies (NYSE-A: OSTX) announced positive results from their Phase 2b clinical trial of OST-HER2, a HER2-targeted immunotherapy for recurrent osteosarcoma with lung metastases.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
A live webcast of the event will be available on the Company’s Investor Relations website at https://investor.t-mobile.com. An on-demand replay will be available shortly after the conclusion of the presentation.
To automatically receive T-Mobile financial news by e-mail, please visit the T-Mobile Investor Relations website, https://investor.t-mobile.com, and subscribe to E-mail Alerts.
About T-Mobile US, Inc.
T-Mobile US, Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250226249744/en/
Investor Contact:
investor.relations@t-mobile.com
Source: T-Mobile US, Inc.